July 16 Johnson & Johnson reported
higher-than-expected second-quarter earnings as strong sales of
prescription drugs and medical devices more than offset anemic
growth of its consumer products.
The diversified healthcare company said on Tuesday that it
earned $3.8 billion, or $1.33 per share. That compared with
$1.41 billion, or 50 cents per share, in the year-earlier
period, when J&J took $2.2 billion in charges for the writedown
of research assets, litigation expenses and merger-related
Excluding special items, J&J earned $1.48 per share.
Analysts on average expected $1.39, according to Thomson Reuters